Global Organ-On-Chip Market - 2024 - 2031

Organ-On-Chip The Global Organ-On-Chip Market reached USD 107.5 million in 2022 and is expected to reach USD 796.7 million by 2031 and is expected to grow with a CAGR of 29.6% during the forecast period 2024-2031. The organ-on-chip market trends show increasing government initiatives and investment in drug development owing to the rising prevalence of oncology and increasing research and development.

Organ-on-chip aims to design human tissue prototypes for disease modeling and drug testing. The organ-on-a-chip employs microfluidics with cells to emulate the physiological and mechanical conditions encountered in the body. The FDA Modernization Act of 2021, presented in Congress in April, would authorize the FDA to utilize “alternative testing methods to animal testing” to assess the safety and efficacy of pharmaceuticals. The bill particularly included organs on chips in its description of a non-clinical test or study.

Furthermore, the numerous advancements, together with rising demand for treatments of several disorders, are driving up the organ-on-chip market size. Due to the expansion of research in these fields, the market is seeing an increase in demand from North American regions. With significant competitors like Organovo Holdings, BiomimX S.r.l., Insphero, and others actively operating in the market, the competition is driving the organ-on-chip market growth.

Market Dynamics

Organ-On-Chip Model an Alternative for Animal Testing Drive The Growth Of the Organ-on-Chip market.

The increasing need for alternatives to animal testing is contributing to the global organ-on-chip market growth in the forecast period. For instance, according to the People for the Ethical Treatment of Animals, annually over 110 million animals including rats, fish, rabbits, dogs, frogs, monkeys, hamsters, mice, cats, guinea pigs, and birds are slaughtered in U.S. laboratories for biology studies, medical internship, curiosity-driven investigation, and chemical, pharmaceutical, food, and cosmetics testing.

A Pew Research Center poll discovered that 52% of U.S. adults resist the usage of animals in scientific investigation, and other surveys indicate that the reserved group that does tolerate animal investigation does so solely because it considers it to be essential for medical advancement. The majority of animal investigations do not contribute to enhancing human health, and the significance of the role that animal investigation recreates in most medical advancements is debatable.

Increasing Market Developments Creates Lucrative Opportunities for Manufacturers.

The increasing market developments such as product launches, collaborations, mergers, acquisitions, etc. in the organ-on-chip market are driving the global market growth in the forecast period. For instance, in September 2021, Fidia Farmaceutici S.p.A. and BiomimX S.r.l. formed a research collaboration planned at presenting and involving new Organs-on-Chip-based specialized solutions to the intra-articular medical device discovery procedure.

Additionally, in November 2021, AIM Biotech rolled out its idenTx 40 Plate, a high-throughput organ-on-a-chip technique allowing investigators at pharmaceutical and biotechnology corporations to simulate the operation of human tissues and organs without exploiting animals for investigation purposes.

Availability of Substituents Will Hamper The Growth Of The Market.

The availability of the substituent in the market to organ-on-chips is hampering the global market growth in the forecast period. The availability of organoids which serves the same purpose of mimicking tissue and organ physiology in the market is a major hurdle for the organ-on-chip market growth during the forecast period.

Moreover, the increasing developments in the organoids market are presenting threats to the global organ-on-chip market in the upcoming forecast years. For instance, on October 3, 2022, AIM Biotech Pte. Ltd. rolled out the organiX System, a 3D tissue culture platform that facilitates the addition of vascularization and immune competence to spheroids, tumor biopsies, and organoids.

Market Segment Analysis

The global organ-on-chip market is segmented based on model, application, end user and region.

The Liver-On-Chip Model Segment Accounted For Approximately 21.4% Of The Organ-On-Chip Market Share In 2022.

The market for organ-on-chip was led by the liver-on-chip model segment, and this trend is expected to continue over the projected period (2023-2030). The liver is the largest internal organ in the human body, and it plays an important role in the creation and metabolism of numerous chemicals, including drug metabolism.

The liver has proven difficult to model due to its wide range of key tasks, which include nutrition and vitamin processing, detoxification, and regulating body metabolism. The inherent limitations of standard two-dimensional (2D) cell culture techniques for researching pharmacokinetics in parenchymal cells (hepatocytes) have resulted in unsatisfactory clinical trials and drug development outcomes. The help of recent advances in microfluidics encourages the creation of highly automated, biomimetic liver-on-a-chip (LOC) devices that imitate natural liver shape and function. For pharmacodynamics, pharmacokinetics, and toxicity research, LOC provides an economical and precise model.

For instance, the Emulate human Liver-Chip faithfully replicates in vivo physiological processes of the human liver via essential microenvironment aspects such as 3D multicellular architecture and vascular flow. Because of these characteristics, the Emulate human Liver-Chip can provide a more faithful representation of the human liver than conventional sandwich cultures, animal models and spheroids.

Market Geographical Share

North America Accounted For Approximately 44.8% Of The Market Share In 2022, Owing To The Strong Presence Of Major Players And Increasing Healthcare Infrastructure Investment.

North America is anticipated to continue being the largest-growing organ-on-chip market in the coming years primarily attributed to the increasing number of organ-on-chip manufacturing companies and the rising demand for organ-on-chip models. Furthermore, factors including rising expenditure on research and development and the growing outsourcing of R&D activities are likely to drive the growth of the region's organ-on-chip market.

Moreover, the growing number of regional clinical trials is responsible for the market’s growth. North America ranks first in the name of clinical trials performed worldwide and various clinical trials are taking place. For instance, in March 2021, Colon Intestine-Chip was introduced by Emulate Inc., a developer of in vitro advanced models, for research on inflammatory intestinal diseases. This colon intestinal chip will provide an overview of the roles of human colon cells, a better knowledge of the mechanisms underlying inflammation, and help identify potential therapeutic targets.

Market Companies

The major global players in the organ-on-chip market include Emulate Inc., Mimetas B.V., Insphero, Organovo Holdings, CN Bio Innovations Ltd, BiomimX S.r.l., AxoSim, Inc., Hesperos Inc., TissUse GmbH and Nortis, Inc. among others.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global organ-on-chip market, owing to the low prevalence and less number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global organ-on-chip market growth over the forecast period.

Key Developments
• On May 5, 2023, Benson Capital Partners kick started its recently launched fund, Benson Capital Fund I, with a strategic investment in AxoSim, Inc., a biotech firm. This marks the first investment made by the firm from the fund. AxoSim, Inc.'s innovative and proprietary technologies, NerveSim and BrainSim, have revolutionized drug development by enabling scientists from top biopharmaceutical companies to predict how the human nervous system will react to therapies much earlier in the drug development process.
• On February 27, 2023, CN Bio Innovations, a company involved in bioengineering and drug discovery announced that the PhysioMimix Single-organ Higher Throughput (HT) System has been launched in the market. The first HT system of company has been developed to overcome barriers to adoption that currently hindering the application of predictive human liver models in drug discovery workflows, allowing use at earlier phases where larger-scale examinations that analyze the efficacy, disposition, or security of lead candidate drugs are required.
• On September 19, 2022, Adeno-associated virus (AAV) transduction usage for the Liver-Chip was released by Emulate, Inc., a leading producer of next-generation in vitro models. This application enables gene therapy researchers to test the safety and effectiveness of AAV vectors for delivery in a verified, human-relevant liver model and get results in few weeks instead of months as with animal models. With the aid of this technique, they can quickly refine the AAV design and speed up the development of gene treatments.

Why Purchase the Report?
• To visualize the global organ-on-chip market segmentation based on model, application, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of organ-on-chip market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global organ-on-chip market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies